Key takeaways
Tremfya (guselkumab) and Entyvio (vedolizumab) are both monoclonal antibody medications used to treat inflammatory conditions, but they differ in their specific uses and mechanisms. Both medications are used for moderate-to-severe ulcerative colitis and Crohn's disease in adults, but Tremfya is approved for moderate-to-severe plaque psoriasis and active psoriatic arthritis. Tremfya works by blocking interleukin-23 (IL-23) to reduce inflammation, whereas Entyvio targets integrins on immune cells to lower inflammation. Tremfya is administered as a subcutaneous injection every 8 weeks after initial doses, while Entyvio can be given as an intravenous infusion every 2 months or as a subcutaneous injection every 2 weeks. Both Tremfya and Entyvio are only available as brand-name medications. Common side effects of Tremfya include upper respiratory infections and headaches, while Entyvio may cause headaches, joint pain, and infections. Both medications can increase the risk of infections due to their effects on the immune system.
